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Abstract
Objective Rituximab is an effective treatment for children with steroid dependent or frequently relapsing nephrotic syndrome.
The optimum dosing schedule for rituximab has not been established. We hypothesized that a single low dose of 375 mg/m2
would have comparable outcomes to higher doses in reducing the frequency of relapse and time to B cell reconstitution.
Methods We conducted a multicenter retrospective observational cohort study of children with steroid-sensitive frequently
relapsing nephrotic syndrome. Data were extracted from clinical records including the dates of diagnosis, treatment, relapses,
the use of concomitant immunosuppression, and lymphocyte subset profiling. Patients treated earlier received variable doses of
rituximab, although typically two doses of 750mg/m2. Later, patients received the current regimen of a single dose of 375mg/m2.
The primary outcome was an absence of clinically confirmed relapse 12 months following rituximab administration. Secondary
outcomes weremedian time to relapse, probability of being relapse-free at 6 and 24months and time to reconstitution of CD19+ B
cells.
Results Sixty patients received 143 courses of rituximab. Seven different dosing regimen strategies were used, ranging between
375 and 750 mg/m2 per dose, with administration of 1–4 doses. There was no significant difference in event-free survival at
12months between dosing strategies. The median time to reconstitution of B cells was not significantly different between groups.
Conclusions Use of a single low-dose regimen of rituximab in the management of frequently relapsing nephrotic syndrome does
not affect the probability of relapse at 12 months or time to B cell reconstitution compared to a conventional higher dose.
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Introduction
Idiopathic nephrotic syndrome (NS), defined as heavy pro-
teinuria (protein: creatinine ratio greater than 200 mg/mmol)
with hypoalbuminemia and clinically detectable edema, is the
commonest glomerular disease in childhood, affecting up to
16 per 100,000 children [1]. Histologically, most children
have minimal change disease (MCD); initial sensitivity to cor-
ticosteroids is used as a prognostic tool [2, 3].
The exact pathogenesis of nephrotic syndrome is un-
clear, with a combination of genetic predisposition, circu-
lating factors, environmental/infective triggers and other
mechanisms hypothesized [4–6]. Eighty to 90% of pa-
tients respond to oral corticosteroid therapy, entering re-
mission within 4 weeks. Up to 50% of patients will have
frequently relapsing disease (FRNS)—having two or more
relapses within a 6-month period—and/or steroid depen-
dent disease (SDNS)—relapses on corticosteroids or with-
in 2 weeks of withdrawal [7, 8].
Additional immunosuppressive agents are often required to
minimize steroid toxicity in FRNS/SDNS patients. Examples
include the anti-helminthic levamisole, alkylating agents such
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as cyclophosphamide, calcineurin inhibitors (CNIs) such as
ciclosporin or tacrolimus and anti-proliferative agents like myco-
phenolate mofetil (MMF). None are free of adverse effects or the
need for regular monitoring, and all place a concordance burden
on the patient and family. Some patients continue to frequently
relapse and require corticosteroids despite multiple adjunctive
therapies; managing these patients is often a challenge.
Rituximab (RTX) is a chimeric murine-human–anti-CD20
monoclonal antibody, which inhibits CD20-mediated B cell
proliferation and differentiation. Developed initially for treat-
ment of B cell non-Hodgkin’s lymphoma [9], RTX has found
utility in other diseases including connective tissue disorders
and nephrotic syndrome [10, 11]. Usage in FRNS and SDNS
has been proven to induce remission and reduce steroid load
[12–14].
The optimum dose of RTX in NS has not been determined,
with initial dosing strategies based on an established regimen
used in lymphoma management. In the UK, a national policy
statement recommends two doses of 750 mg/m2 on day 1 and
15 [15]. More recently a single dose of 375 mg/m2 has been
shown to be effective, with even lower doses used in a more
recent study [16–18]. The indications for repeated administra-
tion of RTX and the timing of such in relation to avoidance of
relapse is also unclear.
Based on our collective experience of RTX usage, we hy-
pothesized that a single dose of 375 mg/m2 had a similar rate
of relapse compared to the standard recommended treatment
of two doses of 750 mg/m2.
Patients and methods
This was a multicenter, retrospective, observational, cohort
study. Children with NS in Scotland, the North-East of
England and the East Midlands, East of England, and South
Yorkshire Network were identified via electronic databases
and clinician recollection. All children with SDNS or FRNS
who received at least one dose of RTX from January 1, 2007,
to January 1, 2017, were included. Patients with initial steroid
resistance or a subsequent diagnosis other than MCD or focal
segmental glomerulosclerosis (FSGS) on biopsy were exclud-
ed. Administration of other immunosuppressive therapies was
not an exclusion criterion. Additional immunosuppressive
therapies were used according to local protocols (adapted
from KDIGO guidance) [19].
Clinical and electronic records were reviewed to collect
data including basic demographics, date of initial diagnosis,
histological diagnosis (if available), date of first administra-
tion of RTX, age at first administration of RTX, date of sub-
sequent courses, date of clinical relapse, use of concomitant
immunosuppression and results of all measurements of
CD19+ B cells from lymphocyte subset profiling.
RTX (MabThera™) was administered as per local proto-
cols (supplementary information Table 1). A course of RTX
was defined as between one and four doses given within a 4-
week period. High dose was defined as 1.5 g/m2 (administered
as 750 mg/m2 in two doses or 375 mg/m2 in four doses). Low
dose was defined as 375 mg/m2 given once. Intermediate
doses were all other regimens.
The primary outcome was the probability of remaining
relapse-free 12 months following RTX administration.
Relapse was defined on standard clinical criteria
(supplementary Table 2). Secondary outcomes included the
time from last dose of RTX to B cell reconstitution (defined
as CD19+ B cells greater than 0.2 × 109/L), the 6 and 24-
month probabilities of relapse, and the requirement for addi-
tional immunosuppression following RTX administration.
Patients were followed up for a maximum of 24 months
and data censored beyond this time point.
Statistical analysis
Event-free survival (EFS) to the fixed end points of 6, 12, and
24months was analyzed using chi-squared tests of association
between treatment group and outcome. EFS up to 24 months
was analyzed using Kaplan-Meier survival curves, construct-
ed using either the time to relapse (if less than 24 months) or a
censored time at last known, event-free follow up or at
24 months (whichever was sooner). Children who received a
prophylactic dose of RTX prior to relapse were treated as
censored at the date of administration of the prophylactic dose.
Log rank tests were carried out on the same basis. Analysis
was carried out to compare the dosing strategies, first versus
subsequent course of treatment, number of concomitant im-
munosuppressants, age at diagnosis (either Btypical^, 2–
11 years, or Batypical,^ < 2 years and > 11 years) and sex of
patient. As many patients received more than a single course,
all data were also analyzed for the first course only, to limit
usage of non-independent data and exclude carryover effects.
CD19+ B cell depletion time was not defined as an a priori
outcome during our study. CD19+ B cell values were mea-
sured at variable intervals in different patients so the exact
time that they reached > 0.2 × 109/L was not known.
Therefore, data were analyzed using three definitions for time
to reconstitution: earliest possible time (1 day after the last
measurement < 0.2 × 109/L); latest possible time (1 day prior
to the measurement of > 0.2 × 109/L); the mean time between
these two. Analysis of B cell reconstitution was by Kaplan
Meier survival curves and log rank tests. A further analysis
was performed using time until CD19+ B cell count returned
to > 1%; however, this was less informative since the required
data were only available for the patients from two centers.
Statistical analyses were performed using Minitab version
17 and R 3.4.0.
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Results
A total of 60 patients with a diagnosis of FRNS/SDNS re-
ceived at least one dose of RTX between January 1, 2007,
and January 1, 2017. Thirty-eight (63.3%) patients were male.
Fifty-nine patients received their first course of RTX in our
centers, with one patient transferring into the region having
previously received one course elsewhere. There were a total
of 143 courses of RTX. Median age at diagnosis was 4 years
(range 1–14 years) and the median age of administration of the
first dose of RTX was 11 years (range 4–17 years). Forty-one
patients had a histological diagnosis; 36 showed minimal
change disease, with the remaining five showing FSGS.
Table 1 summarizes patient characteristics and dosing
strategies.
Time to relapse
Whole cohort (including subsequent and prophylactic doses)
There was no significant difference in the incidence of clinical
relapse at 12 months between the different dosing groups (p =
0.15) with an event-free survival of 53%, 71%, and 47% for
the high, intermediate, and low-dose groups respectively.
Survival analysis did not demonstrate significance on cumu-
lative event-free survival by dosing regimen (p = 0.32)
(Fig. 1).
During the study 26 patients received a subsequent dose of
RTX prior to a clinical diagnosis of relapse, i.e., prophylacti-
cally, at a median of 179 days (range 51–540 days) after their
previous dose. These patients were censored at the time of
their prophylactic dose for the purpose of EFS. Dosing for
(non-prophylactic) subsequent doses was not the same across
the cohort, with variable time-frames, dosing and correlation
with B cell numbers. We therefore analyzed patients after the
first dose only to eliminate confounding variables.
First dose of RTX only
Following their initial course of RTX, 40 (68%) of 59 patients
had at least one relapse. Nine (15%) patients had 24-month
follow-up with no relapse. Five (8%) patients had no relapse,
but with follow-up less than 24-months, with data censored at
latest follow-up. Five (8%) patients received a prophylactic
second dose prior to clinical relapse, with data censorship at
the time of administration of the second course, Table 2.
It is important to note that the intermediate group contains
only 5 patients. This limits statistical comparisons and as such
further chi-squared analysis was performed by grouping the
intermediate group with the higher dose, this produces similar
results at 6 months (chi-squared p = NS), 12-months (p =
0.12) and 24 months (0.0056).
The incidence of relapse in the 24 months following the
first administration of RTX was different between dosing
strategies; high (71%), intermediate (25%), and low (72%)
groups (supplemental Table 3). However, there were only 5
patients whose first course of treatment was at the intermedi-
ate dosing level and a single-patient relapsed. The median
time to relapse after the first dose by Kaplan-Meier survival
analysis was 344, > 720 and 334 days for high, intermediate,
and low-dose groups. A log-rank test comparing the survivor
curves approached significance (p = 0.05), though the smaller
number of patients for comparison of initial dose limits the
conclusions that may be drawn from this group (Fig. 2).
Adjustment for single variables using Cox proportional
hazard models only demonstrated significance of dosing
schedule for EFS when considering first-dose data alone
(p = 0.02). Other variables showed no significant difference,
including treatment center (p = 0.97), sex (p = 0.90) and age
(p = 0.98). When all dose administrations were modeled, the
difference between dosing regimens became non-significant
Table 1 Patient characteristics and dosing strategies
Patient characteristics
Total number of patients 60
Male 38
Median age at onset of nephrotic syndrome (years) (range) 4 (1–14)
Median age at first dose of RTX (years) (range) 11 (4–17)
Median time from diagnosis to 1st dose (years) 6
Biopsy result
Minimal change disease (MCD) 36
No biopsy performed 19
FSGS 5






Dosing strategies (all doses)
750 mg/m2 × 2 High dose 13
375 mg/m2 × 4 2
750 mg/m2 × 1 Intermediate dose 11
500 mg/m2 × 2 3
500 mg/m2 × 1 7
375 mg/m2 × 2 4
375 mg/m2 × 1 Low dose 103
Dosing strategies (first dose)
750 mg/m2 × 2 High dose 12
375 mg/m2 × 4 2
750 mg/m2 × 1 Intermediate dose 1
500 mg/m2 × 2 3
500 mg/m2 × 1 0
375 mg/m2 × 2 1
375 mg/m2 × 1 Low dose 40
RTX rituximab
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(p = 0.29). EFS between the first dose and subsequent doses is
significant (p = 0.02), suggesting a cumulative effect, Fig. 3.
B cell reconstitution
Excluding the 26 courses given prior to a prophylactic dose,
only 56 of 117 (48%) courses demonstrated reconstitution.
Seven of 117 (12%) did not have any subsequent assessment
of B cell populations. In 54 courses, measurements of B cell
populations did not demonstrate reconstitution at last follow-
up. Three courses had CD19+B cell numbers >0.2 × 109/L
within 1 month of administration (measured at days three,
seven, and 23); then, subsequent lymphocyte profiling with-
out re-dosing demonstrated depletion. In two of these three
courses, B cells did not demonstrate reconstitution during fol-
low-up.
For the overall cohort, the median time to reconstitu-
tion of CD19+ B cells (> 0.2 × 109/L) by survival curve
analysis was 295 days. There was no significant differ-
ence between the high, intermediate and low-dose sched-
ules (259, 304 and 290 respectively) (Table 3, Fig. 4).
Excluding courses never demonstrating reconstitution,
the median time was 226 days.
There was no difference in reconstitution times between the
different dosing groups irrespective of how time to
reconstitution was defined; (i) time to last negative result
(log rank test, p = 0.93); (ii) time to first positive result (p =
0.89); (iii) time to mid-point between these two tests (p =
0.98).
Some groups defined B cell reconstitution as a subset pop-
ulation percentage rather than an absolute number, i.e., CD19+
B cells > 1% of the total. Re-analysis using this alternative
definition did not alter non-significance; the median time to
reconstitution was 342, 314, and 217 for the high, intermedi-
ate and low-dose groups. These data were only available for
patients from two centers and as such conferred smaller pa-
tient numbers.
Safety
Minimal severe adverse events were observed in this pa-
tient cohort. Documentation of minor infusion reactions
was occasionally noted, but in only a single case was it
clinically significant, requiring discontinuation of the infu-
sion. The same patient subsequently had an anaphylactic
reaction to a second dose; further dosing was not
attempted. Two patients developed persistent asymptomat-
ic hypogammaglobinemia, one receiving replacement in-
travenous immunoglobulin, one being managed expectant-
ly. There were no recorded episodes of sepsis.
Fig. 1 Kaplan-Meier estimates of
relapse-free survival curves by
dosing schedule, p = 0.32
Table 2 6, 12, and 24-month
event-free survival (EFS) at
different doses—first treatment
only
Dosing strategy Total number of doses 6-month EFS 12-month EFS 24-month EFS
High 14 12/14 (85.7%) 7/14 (50.0%) 4/14 (28.6%)
Intermediate 5 5/5 (100%) 4/4 (100%) 3/4 (75.0%)
Low 40 30/37 (81.1%) 13/34 (38.2%) 2/30 (6.7%)
Chi-squared value 1.213 5.608 12.069
p value NS 0.06 0.0024
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Concomitant immunosuppression
Though a priori outcomes included concomitant immunosup-
pression, multiple patients were missing information. Data
were available from two out of the three centers. As we have
shown above, single variable analysis using Cox proportional
hazardmodels showed no significant difference between treat-
ment centers (p = 0.97) when analyzing EFS. Analysis of
these patients (39 at time of first RTX) showed all to be on
prednisolone. Choice of concomitant immunosuppression
varied but included a combination of CNIs and MMF. There
was no statistical significance in the number of different im-
munosuppressants at the time of first dose between dosing
regimens (p = 0.060). Multi-variable analysis using Cox pro-
portional hazard models was used to test for any effect of
concomitant immunosuppression in addition to dosing
regimen on EFS. The number of concomitant immunosup-
pressants at both time of first dose of RTX (p = 0.42) and at
6-month post-dose (p = 0.24) did not demonstrate
significance.
Discussion
This multicenter study demonstrates that a single dose of RTX
of 375 mg/m2 has a similar outcome rate in suppressing
CD19+ B cells and maintaining remission in pediatric patients
with SDNS or FRNS compared to higher doses (up to 1.5 g/
m2) at 6 months, but this is less convincingly the case at
12 months. At 24 months, low dose is inferior to high and
intermediate dosing. Despite very low numbers in the inter-
mediate group, statistically significant improvement in
Fig. 2 Kaplan-Meier survival
curves of time relapse-free
survival by dose schedule for first
dose of rituximab (RTX) only
(p = 0.05)
Fig. 3 Kaplan-Meier estimates of
survivor curves by course of
treatment, p = 0.02
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relapse-free survival was seen. This study is underpowered to
definitively determine whether this is related to the low patient
numbers within that group but highlights that low-dose regi-
mens may not be as effective in the longer term.
Rituximab usage in pediatric nephrotic syndrome was first
reported in 2004 [20], using 375 mg/m2 weekly for 4 weeks.
Subsequently, RTX has been widely reported to be efficacious
in FRNS/SDNS with multiple dosing strategies [12, 14, 18,
21–25]. The largest randomized placebo-controlled trial of
RTX in NS administered four weekly doses of 375 mg/m2,
reporting a median relapse-free period of 267 days in the RTX
group compared to 101 days with placebo (hazard ratio 0.27,
p = < 0.0001) [14]. Twometa-analyses of RTX in pediatric NS
both demonstrated an improved relapse-free survival with
RTX compared to other immunotherapies (relapse-free sur-
vival hazard ratio of 0.49 (p = 0.03)) [26] and relative risk of
remaining relapse-free at 6 months of 5.25, p < 0.0001) [27].
Fujinaga reported 24-month relapse rates on a low-dose
regimen, reporting 91% relapse (39 patients) at a median of
586 days [28]. Greater risk of relapse was associated with
younger age of administration and more rapid reconstitution
of B cells [28].
In our cohort, the statistical significance of increased re-
lapse rate at 24 months for low dose compared to intermediate
dose is highly influenced by the small numbers in the latter
group—only 1/5 patients relapsed (Fig. 2). If a second patient
had relapsed, significance would have been negated.
Therefore, this prevents any firm conclusion that the low-
dose regimen is non-inferior at 24 months.
Hogan et al in their study compared 100 mg/m2 with
375 mg/m2 and 750 mg/m2 (as two divided doses). They
showed a slightly shorter time to B cell reconstitution
with the 375 mg/m2 group compared with our cohort
(150 days vs 290 days), but a longer event-free survival
at 12 months (59% vs 38%). They concluded increased
dosing is associated with increased time to B cell recon-
stitution, which is in contrast to our results [18]. It should
be noted that they also had small numbers in their low-
dose (8) and high-dose groups (18).
Weaning/cessation of other immunosuppression is of-
ten performed following RTX administration, though the
evidence supporting this approach remains limited. Some
centers are reported to have discontinued all immunosup-
pression while the B cell number is suppressed [12].
Though we intended to investigate this relationship in
detail, we only had data available from two centers.
This demonstrated no significant effect on EFS when
immunosuppression at 6 months was added to treatment
groups in a Cox proportional hazards model. There was a
trend towards longer EFS in patients on less concomitant
Fig. 4 Kaplan-Meier survival (by
interval censored analysis) of the
time to B cell reconstitution, >
0.2 × 109/L between high,
intermediate, and low groups
Table 3 Time to B cell reconstitution (days)
Dosage Number of doses with
data available
Median time to B cell
reconstitution (days) > 0.2 × 109
Number of doses
with data available
Median time to B cell
reconstitution (days) > 1%
High dose 14 259 12 342
Intermediate dose 25 304 12 314
Low dose 96 290 37 217
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immunosuppression (both prednisolone and other
agents). We suggest this reflects patients with a better
clinical course following RTX being more likely to have
reduction in immunosuppression. However, due to the
small numbers where data is available, firm conclusions
cannot be drawn.
The definition of CD19+ B cell reconstitution is not stan-
dardized; some authorities report a percentage of the B cell
population, others use an absolute number. We have presented
our data in both formats (where available). Themedian time to
reconstitution is comparable to other studies (Table 4) [12, 14,
16–18, 21, 24, 29].
Following the initial dose of RTX, 19 patients (32%) of our
cohort did not relapse. This occurred across all dosing groups.
Current practice in the UK is often to consider RTX after
failure of other immunosuppressive strategies; this demon-
strates the potential efficacy of low-dose RTX in
Bcomplicated^ nephrotic syndrome. If a single intravenous
dose leads to long-term remission in a quarter of patients, this
could avoid the long-term accrual of risk currently associated
with other agents used and has utility in patients with concor-
dance issues. Arguably, it might be better used earlier in
FRNS/SDNS algorithms [30].
Prophylactic use of RTX has been described in a time-
dependent fashion [31]. Though reducing the likelihood
of relapse, prophylactic dosing leads to administration to
patients never destined to relapse. Further work is
required to determine which patients may benefit from
prophylactic administration. We agree with a recent re-
view article, suggesting large-scale trials to ascertain the
correct dosing regimen to balance effectiveness with safe-
ty and cost-benefits [32].
Rituximab is not a benign medication. Long-term adverse
effects remain unknown due to the relative novelty of the drug.
Minimization of drug exposure may reduce overall adverse
effects, though these data are lacking. RTX is a relatively ex-
pensive medication; usage of the low-dose regimen reduces
immediate medication costs by 75%, before accounting for sav-
ings from reduced hospital attendance for repeated infusions.
Limitations of this study include the retrospective and ob-
servational nature of the cohort, with no randomization of
therapy or blinding. Selection and systematic bias cannot be
excluded. Patients treated earlier in the study were more likely
to receive the larger doses. Other aspects of their treatment
may also have differed, e.g., choice of CNIs. Many of the
low-dose group had a shorter follow-up so required censoring
for last follow-up and relapse-free time. Withdrawal of other
immunosuppression was variable and managed by individual
clinicians. Data were not collected on minor adverse events
for all patients, so it is not possible to comment on whether the
lower dose regimen had fewer self-limiting adverse effects.
Finally, due to a number of patients receiving a combination
of high, intermediate and low doses, demographic bias be-
tween dosing schedules cannot be taken into consideration.
Table 4 Comparative relapse and remission data with other reports following first dose of rituximab (RTX)
Study Year Diagnosis Dose No.
patients












59 Median depletion 10 months 84% 46% 11 months
1 × 375 mg/m2 40 Median depletion 10 months 81% 38% 11 months
Niu et al 2016 SDNS Single dose
375 mg/m2
19 Mean depletion time
3 months
74% 63% 5 months
Ravani et al 2015 SDNS Single dose
375 mg/m2
15 Mean depletion 6 months 93% 66% 18 months
(between RTX
treatments)
Iijima et al 2014 FRNS or
SDNS
4 doses 375 mg/m2 20 Median depletion lasted
5 months
– 15% 9 months
Tellier et al 2013 SDNS 1–4 doses 375 mg/m2
(10 patients
received 4)
18 – – – 13 months
Sellier-Leclerc
et al
2012 SDNS 1–4 doses 375 mg/m2
(15 patients
received 4)
30 Median depletion 8 months – – –
Ravani et al 2011 SDNS 1–2 doses of
375 mg/m2
27 – 50% 25% –
Sinha et al 2015 SDNS 1–4 doses of
375 mg/m2
101 – 92% 58% 16 months
Hogan et al 2018 SDNS 1 dose of 375 mg/m2 35 Median depletion 5 months – 59% –
EFS event-free survival, SDNS steroid-dependent nephrotic syndrome, FRNS frequently relapsing nephrotic syndrome
*Excludes patients receiving prophylactic dosing and those with no subsequent relapse
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Strengths of this study are the inclusion of multiple patients
with a relatively homogenous population and a small number
of clinicians. Sixty pediatric patients receiving 143 courses of
RTX represents one of the largest cohorts reported to date.
Conclusion
A low-dose regimen for RTX of a single dose of 375 mg/m2 is
similarly effective to higher dosing regimens in the treatment
of steroid sensitive, frequently relapsing nephrotic syndrome
at 6 and 12 months. However, this is not the case at 24 months
and as such a higher dose may be beneficial for the initial
treatment when longer follow-up is complete, but this study
was underpowered to confirm conclusively. As many centers
are reporting outcomes with a lower dose regimen, further
work is required to establish the minimum effective dose,
the role of prophylactic dosing, and the role of concomitant
immunosuppression.
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